/PRNewswire/ Multiple System Atrophy is a rare neurodegenerative ailment affected numerous individuals worldwide. Living with MSA is extremely difficult.
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
- Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
- The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
- Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
News provided by
Share this article
LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in
JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal
PRESS RELEASE Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life Lund, Sweden - 10 May 2021 - Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal®) versus daily sublingual buprenorphine.